Cargando…
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Recent randomized controlled trials (RCTs) tested the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to specifically treat nonalcoholic fatty liver disease (NAFLD). We systematically searched three electronic databases (up to 31 October 2020) for identifying placebo-controlled or hea...
Autores principales: | Mantovani, Alessandro, Petracca, Graziana, Csermely, Alessandro, Beatrice, Giorgia, Targher, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823667/ https://www.ncbi.nlm.nih.gov/pubmed/33396949 http://dx.doi.org/10.3390/metabo11010022 |
Ejemplares similares
-
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2021) -
Long-Term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study
por: Mantovani, Alessandro, et al.
Publicado: (2022) -
Association between Higher Circulating Leucine-Rich α-2 Glycoprotein 1 Concentrations and Specific Plasma Ceramides in Postmenopausal Women with Type 2 Diabetes
por: Mantovani, Alessandro, et al.
Publicado: (2022) -
Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
por: Dokmak, Amr, et al.
Publicado: (2019) -
Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study
por: Mantovani, Alessandro, et al.
Publicado: (2022)